Hormonal contraception: venous and arterial disease

References

• Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117:19–25.
   PubMed Web of Science ®Google Scholar
• Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, et al. Estrogens, progestogens and thrombosis. J Thromb Haemost. 2003;1:1371–1380.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ovunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–952.
   PubMed Web of Science ®Google Scholar
• O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case control study. Lancet. 2010;376:112–123.
   PubMed Web of Science ®Google Scholar
• Siegerink B, Maino A, Algra A, et al. Hypercoagulability and the risk of myocardial infarction and ischemic stroke in young women. J Thromb Haemost. 2015;13:1568–1575.
   PubMed Web of Science ®Google Scholar
• Raffetto JD, Qiao X, Beauregard KG, et al. Estrogen receptor-mediated enhancement of venous relaxation in female rat: implications in sex-related differences in varicose veins. J Vasc Surg. 2010;51:972–981.
   PubMed Web of Science ®Google Scholar
• Ceballos C, Ribes C, Amado JA, et al. Venous endothelial function in postmenopausal women who are receiving long-term estrogen and progestagen therapy. Fertil Steril. 2000;74:268–273.
   PubMed Web of Science ®Google Scholar
• Wood JE III, Goodrich SM. Dilation of the veins with pregnancy or with oral contraceptive therapy. Trans Am Clin Climatol Assoc. 1964;76:174–180.
   PubMedGoogle Scholar
• Fawer R, Dettling A, Weihs D, et al. Effect of the menstrual cycle, oral contraception and pregnancy on forearm blood flow, venous distensibility and clotting factors. Eur J Clin Pharmacol. 1978;13:251–257.
   PubMed Web of Science ®Google Scholar
• Wattanakit K, Lutsey PL, Bell EJ, et al. Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A time-dependent analysis. Thromb Haemost. 2012;108:508–515.
   PubMed Web of Science ®Google Scholar
• Ezihe-Ejifor JA, Hutchinson N. Anticlotting mechanisms I: physiology and pathology. Contin Educ Anaesth Crit Care Pain. 2013;13:87–92.
   Google Scholar
• Norris LA, Bonnar J. Haemostatic changes and the oral contraceptive pill. Baillieres Clin Obstet Gynaecol. 1997;11:545–563.
   PubMed Web of Science ®Google Scholar
• Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicentre study. Contraception. 2003;67:173–185.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware RL, Menard J, Rad M, et al. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab. 2007;92:2074–2079.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Lee JH, Kutschera E, et al. Effect of four oral contraceptives on hemostatic parameters. Contraception. 2004;70:97–106.
   PubMed Web of Science ®Google Scholar
• Kluft C, Endrikat J, Mulder SM, et al. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. Contraception. 2006;73:336–343.
   PubMed Web of Science ®Google Scholar
• Bagot CN, Marsh MS, Whitehead M, et al. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J Thromb Haemost. 2010;8:1736–1744.
   PubMed Web of Science ®Google Scholar
• Schindler AE, Campagnoli C, Druckmannc R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(Suppl. 1):S7–S16.
   PubMed Web of Science ®Google Scholar
• Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids. 2011;76:636–682.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Minnetti M, Sbardella E, et al. Mechanisms in endocrinology: The spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur J Endocrinol. 2015;173:R101–R113.
   PubMed Web of Science ®Google Scholar
• Herkert O, Kuhl H, Sandow J, et al. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation. 2001;104:2826–2831.
   PubMed Web of Science ®Google Scholar
• Kuhl H. Effects of progestogens on haemostasis. Maturitas. 1996;24:1–19.
   PubMed Web of Science ®Google Scholar
• Rad M, Kluft C, Ménard J, et al. Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. Am J Obstet Gynecol. 2006;195:72–77.
   PubMed Web of Science ®Google Scholar
• Rad M, Burgraaf J, de Kam ML, et al. Discriminant analysis of the metabolic effects of a new combined contraceptive vaginal ring containing Nestorone/EE vs. a second generation oral contraceptive containing levonorgestrel/EE. Contraception. 2012;86:231–237.
   PubMed Web of Science ®Google Scholar
• van Vliet HA, Bertina RM, Dahm AE, et al. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost. 2007;6:346–351.
   PubMed Web of Science ®Google Scholar
• Darney PD. The androgenicity of progestins. Am J Med. 1995;98(Suppl. 1A):104–110.
   Web of Science ®Google Scholar
• Deckers GH, Schoonen WG, Kloosterboer HJ. Influence of the substitution of 11-methylene, delta(15), and/or 18-methyl groups in norethisterone on receptor binding, transactivation assays and biological activities in animals. J Steroid Biochem Mol Biol. 2000;74:83–92.
   PubMed Web of Science ®Google Scholar
• Kuhnz W, Fritzemeier KH, Hegele-Hartung C, et al. Comparative progestational activity of norgestimate, levonorgestrel-oxime and levonorgestrel in the rat and binding of these compounds to the progesterone receptor. Contraception. 1995;51:131–139.
   PubMed Web of Science ®Google Scholar
• Hammond GL, Abrams LS, Creasy GW, et al. Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception. 2003;67:93–99.
   PubMed Web of Science ®Google Scholar
• Hugon-Rodin J, Gompel A, Plu-Bureau G. Epidemiology of hormonal contraceptives-related venous thromboembolism. Eur J Endocrinol. 2014;171:R221–R230.
   PubMed Web of Science ®Google Scholar
• Raps M, Helmerhorst F, Fleischer K, et al. Sex hormone-binding globulin as a marker of the thrombotic risk of hormonal contraceptives. J Thromb Haemost. 2012;10:992–997.
   PubMed Web of Science ®Google Scholar
• Kluft C, Skouby SO, Jespersen J, et al. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives: a rebuttal. J Thromb Haemost. 2013;11:394–395.
   PubMed Web of Science ®Google Scholar
• Bateson D. Risk of venous thromboembolism in women taking the combined oral contraceptive: a systematic review and meta-analysis. Aust Fam Physician. 2016;45:59–67.
   PubMed Web of Science ®Google Scholar
• Ruan X, Seeger H, Mueck AO. The pharmacology of dienogest. Maturitas. 2012;71:337–344.
   PubMed Web of Science ®Google Scholar
• Fuhrmann U, Krattenmacher R, Slater EP, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996;54:243–251.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric. 2005;8(Suppl. 3):4–12.
   PubMed Web of Science ®Google Scholar
• Gromotowicz-Poplawska A, Stankiewicz A, Kramkowski K, et al. The acute prothrombotic effect of aldosterone in rats is partially mediated via angiotensin II receptor type 1. Thromb Res. 2016;138:114–120.
   PubMed Web of Science ®Google Scholar
• Sawathiparnich P, Kumar S, Vaughan DE, et al. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab. 2002;87:448–452.
   PubMed Web of Science ®Google Scholar
• Africander D, Louw R, Hapgod JP. Investigating the anti-mineralocorticoid properties of synthetic progestins used in hormone therapy. Biochem Biophys Res Commun. 2013;433:305–310.
   PubMed Web of Science ®Google Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62:29–38.
   PubMed Web of Science ®Google Scholar
• Regidor PA, Colli E, Schindler AE. Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 μg per day. Gynecol Endocrinol. 2016;32:794–751.
   Web of Science ®Google Scholar
• Franceschini SA, Vieira CS, Martins WP, et al. Effects of combined oral contraceptives containing levonorgestrel or chlormadinone on the endothelium. Contraception. 2013;87:766–772.
   PubMed Web of Science ®Google Scholar
• Thompson AK, Przemska A, Vasilopoulou D, et al. Combined oral contraceptive pills containing desogestrel or drospirenone enhance large vessel and microvasculature vasodilation in healthy premenopausal women. Microcirculation. 2011;18:339–346.
   PubMed Web of Science ®Google Scholar
• Meenderinga JR, Torgrimsona BN, Millera NP, et al. Ethinyl estradiol-to-desogestrel ratio impacts endothelial function in young women. Contraception. 2009;79:41–49.
   PubMed Web of Science ®Google Scholar
• Giribela CRG, Meloa NR, Silva RCG, et al. A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: a prospective clinical trial. Contraception. 2012;86:35–41.
   PubMed Web of Science ®Google Scholar
• Ruan X, Seeger H, Mueck AO. The pharmacology of nomegestrol acetate. Maturitas. 2012;71:345–353.
   PubMed Web of Science ®Google Scholar
• Oelkers WKH. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids. 1996;61:166–171.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Kutschera E, Lee JH, et al. Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters. Contraception. 2003;67:361–366.
   PubMed Web of Science ®Google Scholar
• Skinner SL, Lumbers ER, Symonds EM. Alteration by oral contraceptives of normal menstrual changes in plasma renin activity, concentration and substrate. Clin Sci. 1969;36:67–76.
   PubMed Web of Science ®Google Scholar
• Grandi G, Napolitano A, Cagnacci A. Metabolic impact of combined hormonal contraceptives containing estradiol. Exp Opin Drug Metab Toxicol. 2016;12:779–787.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Zanin R, Napolitano A, et al. Modification of 24-h ambulatory blood pressure and heart rate during contraception with the vaginal ring: a prospective study. Contraception. 2013;88:539–543.
   PubMed Web of Science ®Google Scholar
• Junge W, Mellinger U, Parke S, et al. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single centre study. Clin Drug Invest. 2011;31:573–574.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware RL, Menard J, Rad M, et al. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. Contraception. 2007;75:430–437.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Ferrari S, Napolitano A, et al. Combined oral contraceptive containing drospirenone does not modify 24-h ambulatory blood pressure but increases heart rate in healthy young women: prospective study. Contraception. 2013;88:413–417.
   PubMed Web of Science ®Google Scholar
• de Nadai MN, Nobre F, Ferriani RA, et al. Effects of two contraceptives containing drospirenone on blood pressure in normotensive women: a randomized-controlled trial. Blood Press Monit. 2015;20:310–315.
   PubMed Web of Science ®Google Scholar
• Dinger J, Möhner S, Heinemann K. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives. Contraception. 2016;93:378–385.
   PubMed Web of Science ®Google Scholar
• Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev. 2014;4:CD006133.
   PubMed Web of Science ®Google Scholar
• Corbould A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol. 2007;192:585–594.
   PubMed Web of Science ®Google Scholar
• Godsland IF, Walton C, Felton C, et al. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab. 1992;74:64–70.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Paoletti AM, Renzi A, et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab. 2003;88:3621–3625.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Ferrari S, Tirelli A, et al. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial. Contraception. 2009;79:111–116.
   PubMed Web of Science ®Google Scholar
• Agren UM, Anttila M, Maenpaa-Liukko K, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 2011;16:444–457.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Piacenti I, Zanin R, et al. Influence of an oral contraceptive containing drospirenone on insulin sensitivity of healthy women. Eur J Obstet Gynecol Reprod Biol. 2014;178:48–50.
   PubMed Web of Science ®Google Scholar
• Salazar MR, Carbajal HA, Espeche WG, et al. Identifying cardiovascular disease risk and outcome: use of the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio versus metabolic syndrome criteria. J Intern Med. 2013;273:595–601.
   PubMed Web of Science ®Google Scholar
• Knopp RH, Zhu X, Bonet B. Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women. Atherosclerosis. 1994;110(Suppl):S83–S91.
   PubMed Web of Science ®Google Scholar
• La Rosa JC. The varying effects of progestins on lipid levels and cardiovascular disease. Am J Obstet Gynecol. 1988;158:1821–1829.
   Web of Science ®Google Scholar
• Upton V. Lipids, cardiovascular disease, and oral contraceptives: a practical perspective. Fertil Steril. 1990;53:1–12.
   PubMed Web of Science ®Google Scholar
• Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med. 1990;323:1375–1381.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Stahlberg S, Manthey T, et al. Effects of an oral contraceptive containing 30 μg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use. Contraception. 2010;81:57–61.
   PubMed Web of Science ®Google Scholar
• Grandi G, Piacenti I, Volpe A, et al. Modification of body composition and metabolism during oral contraceptives containing non-androgenic progestins in association with estradiol or ethinyl estradiol. Gynecol Endocrinol. 2014;30:676–680.
   PubMed Web of Science ®Google Scholar
• Winkler UH, Sudik R. The effects of two monophasic oral contraceptives containing 30 μg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters. Contraception. 2009;79:15–23.
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002;65:187–196.
   PubMed Web of Science ®Google Scholar
• van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921
   PubMed Web of Science ®Google Scholar
• Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception. 2016;94:328–339.
   PubMed Web of Science ®Google Scholar
• Martínez F, Ramírez I, Pérez-Campos E, et al. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Contracept Reprod Health Care. 2012;17:7–29.
   PubMed Web of Science ®Google Scholar
• de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;3:CD010813.
   PubMed Web of Science ®Google Scholar
• Reid RL, Westhoff C, Mansour D, et al. Oral contraceptives and venous thromboembolism consensus opinion from an international workshop held in Berlin, Germany, in December 2009. J Fam Plann Reprod Health care. 2010;36:117–122.
   PubMed Web of Science ®Google Scholar
• Thorogood M. Stroke and steroid hormonal contraception. Contraception. 1998;57:157–167.
   PubMed Web of Science ®Google Scholar
• Poulter NR, for WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case–control study. Lancet. 1996;348:505–510.
   PubMed Web of Science ®Google Scholar
• Petitti DB, Sidney S, Bernstein A, et al. Stroke in users of low-dose oral contraceptives. N Engl J Med. 1996;335:8–15.
   PubMed Web of Science ®Google Scholar
• Bonita R. Cigarette smoking, hypertension and the risk of subarachnoid hemorrhage: a population-based case-control study. Stroke. 1986;17:831–835.
   PubMed Web of Science ®Google Scholar
• Schwartz SM, Siscovick DS, Longstreth WT, Jr et al. Use of low-dose oral contraceptives and stroke in young women. Ann Intern Med. 1997;127:596–603.
   PubMed Web of Science ®Google Scholar
• Poulter NR, Chang CL, Farley TMM, et al. Effect on stroke of different progestagens in low oestrogen dose oral contraceptives. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1999;354:301–302.
   PubMed Web of Science ®Google Scholar
• Jick SS, Jick H. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch. Contraception. 2006;74:290–292.
   PubMed Web of Science ®Google Scholar
• Plu-Bureau G, Hugon-Rodin J, Maitrot-Mantelet L, et al. Hormonal contraceptives and arterial disease: an epidemiological update. Best Pract Res Clin Endocrinol Metab. 2013;27:35–45.
   PubMed Web of Science ®Google Scholar
• Hannaford PC, Croft PR, Kay CR. Oral contraception and stroke. Evidence from the Royal College of General Practitioners' Oral Contraception Study. Stroke. 1994;25:935–942.
   PubMed Web of Science ®Google Scholar
• Poulter NR. for the WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case–control study. Lancet. 1996;348:498–505.
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Kreiner S. Contraceptives and cerebral thrombosis: a five-year national case-control study. Contraception. 2002;65:197–205.
   PubMed Web of Science ®Google Scholar
• Weill A, Dalichampt M, Raguideau F, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ. 2016;353:i2002.
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Løkkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257–2266.
   PubMed Web of Science ®Google Scholar
• Khader YS, Rice J, John L, et al. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception. 2003;68:11–17.
   PubMed Web of Science ®Google Scholar
• Baillargeon J-P, McClish DK, Essah PA, et al. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab. 2005;90:3863–3870.
   PubMed Web of Science ®Google Scholar
• Roach RE, Helmerhorst FM, Lijfering WM, et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015;8:CD011054.
   PubMed Web of Science ®Google Scholar
• Poulter NR. for the WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case–control study. Lancet. 1997;349:1202–1209.
   PubMed Web of Science ®Google Scholar
• Lewis MA, Heinemann LAJ, Spitzer WO, et al. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception. 1997;56:129–2140.
   PubMed Web of Science ®Google Scholar
• Tanis BC, van den Bosch MAAJ, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 2001;345:1787–1793.
   PubMed Web of Science ®Google Scholar
• Spitzer WO, Faith JM, MacRae D. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Hum Reprod. 2002;17:2307–2314.
   PubMed Web of Science ®Google Scholar
• Dunn NR, Arscott A, Thorogood M. The relationship between use of oral contraceptives and myocardial infarction in young women with fatal outcome, compared to those who survive: results from the MICA case–control study. Contraception. 2001;63:65–69.
   PubMed Web of Science ®Google Scholar
• Sidney S, Cheetham TG, Frederick A, et al. Recent combined hormonal contraceptives (CHC) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2013;87:93–100.
   PubMed Web of Science ®Google Scholar
• Dinger J, Bardenheuer K, Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception. 2014;89:253–263.
   PubMed Web of Science ®Google Scholar